Food borne Salmonella Typhimurium is a valid concern for the global pork industry. An attenuated oral swine Salmonella Choleraesuis vaccine has proven to be an effective tool for the pre-harvest reduction of carrier rates for multiple Salmonella spp. Serum antibody assays are available to monitor exposure to wild-type Salmonella infection. This clinical study assessed protection induced by an attenuated oral Salmonella Choleraesuis vaccine against challenge infection with S.
Introduction
Salmonella Typhimunum infection in swine reduces growth performance and presents a food safely risk to humans. (Flores et a/, 2002 . CDC, 2005 A commercial swine vaccine has been shown to reduce the carrier rate of pigs infected with various Salmonella spp including S. et al, 2006) Serum antibody tests would be most useful if they did not detect antibodies due to vaccination, while still detecting antibody generated by infection with wild-type Salmonella. This clinical study evaluated heterologous protection and the serum antibody response of pigs vaccinated with attenuated-live S.
Choleraesuis vaccine, followed by challenge with virulent S. Typhimurium.
Materials and Methods
Sixty weaned pigs, approximately 3 weeks of age, were confirmed to be Salmonella serum antibody and fecal culture negative. They were blocked by weight and sex and randomly assigned to 3 treatment groups (n=20/group, • :}0 1 3 20 00-t Following S . Typhimurium challenge, pigs vaccinated with Enterisol® SC-54 had significant reductions 1n pyrexia, clinrcal signs, enteric lesron prevalence and significant improvement in ADG from Day 43 through 57 Vaccinates also demonstrated numeric improvements in ADG from Day 57 through 71 and reduced group weight variation compared to nonvaccinated pigs. These findings confirm the ability of this vaccrne to provide heterologous protection. Vaccination did not result in a significant incidence of seroconversion. However, all pigs challenged with virulent Salmonella Typhrmunum, regardless of vaccination status, seroconverted within 9 days of challenge. Lack of seroconversion in response to vaccination rndicates that this assay IS not suitable as a vaccination compliance tool or as an mdicator of protective immunity. Rapid seroconversion following infection demonstrates the ability of th1s assay to differentiate Salmonella-exposed pigs from non-exposed pigs regardless of vaccination status. The findings from this study support the use of this vaccine to clinically protect pigs from heterologous Salmonella infection, while preserving the ability to use the serologic tool to assess exposure status to wild- 1mprov1ng the food safety profile of pork from vaccinated pigs. The collective effects reported from this and other referenced studtes support broader use of this vaccine, both as a climcal and productivity tool in swine production, as well as a potenttal pre-harvest food safety Improvement measure
Conclusions
The results of this clinical trial indicate • Vaccmat1on of sw1ne w1th Entensol SC-54 provtdes heterologous protect1 on agatnst Salmonella Typhtmunum infectton. a common cause of food borne Salmonella tllness • The IDEXX HerdChek Swtne Salmonella ELISA does not detect a serologtc response to Entensol SC-54 vaccmatton, but wtll detect antibod1 es to Wild-type S. Typh1murium mfecllon regardless of vacc1nat1on status This allows for vaccination w1thout comprom1s1ng serologiC Salmonella momtonng programs usmg th1s assay
